scholarly journals Palbociclib Plus Fulvestrant Maintains Long‐Term Overall Survival Benefit in HR +/ HER2 – Advanced Breast Cancer

2021 ◽  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Advanced Breast Cancer ◽  
Survival Benefit ◽  
Advanced Breast ◽  
Overall Survival Benefit

Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis

2010 ◽  
Vol 36 (1) ◽  
pp. 69-74 ◽  
Author(s):  
Davide Mauri ◽  
Konstantinos Kamposioras ◽  
Lamprini Tsali ◽  
Magdalini Bristianou ◽  
Antonis Valachis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Advanced Breast Cancer ◽  
Survival Benefit ◽  
Meta Analysis ◽  
Advanced Breast ◽  
Overall Survival Benefit

A phase II trial of a neoadjuvant platinum-containing regimen for locally advanced breast cancer: Pathologic response, long-term follow-up, and correlation with biomarkers

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e11510-e11510
Author(s):  
T. N. Shenkier ◽  
M. Hayes ◽  
K. A. Gelmon ◽  
S. Chia ◽  
C. Bajdik ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Advanced Breast Cancer ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast ◽  
Double Negative ◽  
Negative Group

e11510 Background: To determine the response, tolerability, and long-term outcome of a neoadjuvant platinum-containing regimen for locally advanced breast cancer (LABC). To search for correlation between pathologic complete response (pCR) and predefined biomarkers in this cohort. Patients and Methods: Patients with LABC received eight cycles of either sequence A or B. Sequence A was doxorubicin 60 mg/m2 and paclitaxel 175 mg/m2 (AT) q3w X 4 followed by cisplatin (C) 60 mg/m2 and paclitaxel 90 mg/m2 (CT) q2w X 4. Sequence B was CT x 4 followed by AT x 4. In addition to estrogen receptor and HER2, immunohistochemistry (IHC) for MDR-1, MRP-1, topoisomerase IIα(topoIIα) and p53 was performed. Results: 88 patients were evaluable for response and toxicity. Median follow-up was 97 months. The overall pCR rate was 21.5%. For subgroups ER+/HER2-, HER2 +, and double negative (ER-/ HER2-) disease the pCR was 5.9%,23.3% and 35% respectively, p=0.006. Five year(y) overall survival for the entire cohort was 71.1%. Five y overall survival was 88.1% (CI 77.1%, 99.1%) for the ER positive HER2 negative group compared to 68.5% (CI 51.3%, 85.7%) and 49.5 (CI 27.4%, 71.6%) in the HER2 positive and “double negative” group respectively (p=0.0077). Over-expression of topo IIα was correlated with pCR (p<0.001). There were no toxic deaths. Conclusions: A platinum-containing neoadjuvant regimen was well tolerated and achieved a pCR rate which compares favorably to other recent studies of multi-agent chemotherapy. Further studies tailored for specific breast cancer subtypes are required. No significant financial relationships to disclose.

scholarly journals 251P Characteristics and overall survival of an advanced breast cancer cohort in Finland

2020 ◽  
Vol 31 ◽  
pp. S340
Author(s):  
A. Ellonen ◽  
K. Heinolainen ◽  
S. Saarinen ◽  
A. Karlsson ◽  
P. Carlqvist ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Breast Cancer Cohort

Olaparib for advanced breast cancer

2020 ◽  
Vol 16 (12) ◽  
pp. 717-732 ◽  
Author(s):  
Gaia Griguolo ◽  
Maria Vittoria Dieci ◽  
Federica Miglietta ◽  
Valentina Guarneri ◽  
PierFranco Conte
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Parp Inhibitor ◽  
Progression Free Survival ◽  
Advanced Breast ◽  
Phase Iii ◽  
Breast Cancer Patients ◽  
Open Questions ◽  
Overall Survival Benefit

Olaparib, an oral PARP-inhibitor, has shown clinical benefit for HER2-negative advanced breast cancer patients carrying a germinal BRCA1/2 mutation. In a randomized Phase III trial, olaparib significantly prolonged progression-free survival as compared with chemotherapy of physician choice. Moreover, in the same trial, a prespecified subgroup analysis reported an overall survival benefit for patients not previously pretreated with chemotherapy for metastatic disease. This review focuses on available preclinical, pharmacokinetic and pharmacodynamic data regarding olaparib and clinical evidence of its antitumor efficacy (both as monotherapy and in combination) and tolerability in breast cancer patients. Open questions, such as use of appropriate biomarkers for patient selection and combination/sequencing with other anticancer drugs, are also addressed.

scholarly journals Expanding Application of the Long-Term Quality of Life Instrument to the Population of Women Undergoing Treatment of Advanced Breast Cancer

2019 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Kendra Kamp ◽  
Megan Flanigan ◽  
Kanjana Thana ◽  
Jodi Terpstra ◽  
Gwen Wyatt ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Life Instrument
Sign in / Sign up

Export Citation Format

Share Document